Methotrexate Afortas: Uses, Dosage & Side Effects
A folate antagonist and disease-modifying antirheumatic drug (DMARD) used for rheumatoid arthritis, severe psoriasis, and certain cancers
Methotrexate Afortas contains the active substance methotrexate, a folate antagonist that belongs to the class of disease-modifying antirheumatic drugs (DMARDs) and antimetabolites. It is one of the most widely prescribed and well-studied medications in rheumatology, used as the cornerstone first-line treatment for rheumatoid arthritis according to guidelines from the American College of Rheumatology (ACR), the European Alliance of Associations for Rheumatology (EULAR), and the World Health Organization (WHO). Methotrexate is also approved for severe psoriasis that does not respond to other treatments, psoriatic arthritis, and certain types of cancer at higher doses. Available as 2.5 mg tablets, methotrexate is taken once weekly for autoimmune and inflammatory conditions, a critical distinction from its oncological use where different dosing schedules apply. Regular blood monitoring is required throughout treatment to detect potential adverse effects on the liver, bone marrow, and kidneys.
Quick Facts: Methotrexate Afortas
Key Takeaways
- Methotrexate Afortas is the gold-standard first-line DMARD for rheumatoid arthritis, recommended by ACR, EULAR, and WHO guidelines, and is also used for severe psoriasis, psoriatic arthritis, and certain cancers.
- For autoimmune conditions, methotrexate is taken once weekly — never daily. Accidental daily dosing is a known cause of serious and potentially fatal toxicity, including severe bone marrow suppression.
- Folic acid supplementation (typically 5 mg weekly, taken on a different day) is recommended to reduce side effects such as nausea, mouth ulcers, and liver enzyme elevations without reducing efficacy.
- Regular blood monitoring (complete blood count, liver and kidney function tests) is mandatory throughout treatment, typically every 1–2 weeks initially and every 2–3 months once stable.
- Methotrexate is absolutely contraindicated in pregnancy and breastfeeding due to its teratogenic effects. Reliable contraception must be used during treatment and for at least 6 months (women) or 3 months (men) after discontinuation.
What Is Methotrexate Afortas and What Is It Used For?
Methotrexate, the active ingredient in Methotrexate Afortas, was first synthesized in the 1940s as a cancer treatment and was later discovered to have powerful anti-inflammatory and immunomodulatory properties at lower doses. Today, it is recognized as one of the most important medications in all of medicine, included on the WHO Model List of Essential Medicines. In rheumatology, methotrexate is considered the anchor drug for the treatment of rheumatoid arthritis, meaning that other therapies are typically added to methotrexate rather than replacing it.
The primary indications for Methotrexate Afortas include active rheumatoid arthritis in adults, where it is the recommended first-line DMARD by both the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR). It is also indicated for severe psoriasis that has not responded adequately to conventional therapies such as phototherapy, and for psoriatic arthritis. Additionally, at higher doses, methotrexate is used as an antineoplastic agent in the treatment of acute lymphoblastic leukemia, choriocarcinoma, breast cancer, head and neck cancers, osteosarcoma, and certain lymphomas.
At the low doses used for autoimmune and inflammatory conditions (typically 7.5–25 mg once weekly), methotrexate exerts its therapeutic effects primarily through immunomodulation rather than cytotoxic mechanisms. Research has shown that low-dose methotrexate increases extracellular adenosine levels, which activates adenosine receptors on inflammatory cells, leading to suppression of inflammation, reduced production of pro-inflammatory cytokines (such as TNF-alpha, IL-1, and IL-6), and decreased activity of immune cells that drive joint inflammation and tissue damage.
The distinction between methotrexate’s low-dose immunomodulatory use and its high-dose cytotoxic use in oncology is critically important. In autoimmune disease, methotrexate is given as a single dose once weekly, whereas in cancer treatment, dosing schedules are entirely different and determined by oncology protocols. The 2.5 mg tablets in Methotrexate Afortas allow flexible dose adjustments within the typical range of 7.5–25 mg per week (3–10 tablets taken on one designated day each week).
Clinical evidence strongly supports the efficacy of methotrexate in rheumatoid arthritis. Systematic reviews and meta-analyses published in the Cochrane Database demonstrate that methotrexate significantly reduces disease activity, slows joint damage progression as assessed by radiographic outcomes, and improves physical function and quality of life. When started early in the disease course, methotrexate can achieve sustained remission in a substantial proportion of patients, particularly when used as part of a treat-to-target strategy.
What Should You Know Before Taking Methotrexate Afortas?
Methotrexate is a potent medication that requires careful patient selection and thorough baseline assessment before initiating treatment. Your prescribing physician—typically a rheumatologist, dermatologist, or oncologist—will conduct a comprehensive evaluation to ensure that the benefits of methotrexate therapy outweigh the potential risks in your individual case. Understanding the contraindications, warnings, and precautions is essential for safe and effective use of this medication.
Contraindications
Methotrexate Afortas must not be used in the following situations:
- Pregnancy and breastfeeding: Methotrexate is a known teratogen (Category X). It causes embryotoxicity, miscarriage, and severe birth defects. It is excreted in breast milk and can harm the nursing infant.
- Severe hepatic impairment: Pre-existing significant liver disease, including alcoholic liver disease, hepatic fibrosis, or cirrhosis, as methotrexate can cause further hepatotoxicity.
- Severe renal impairment: Creatinine clearance below 20 mL/min, as methotrexate is primarily eliminated through the kidneys and accumulation can lead to severe toxicity.
- Pre-existing blood dyscrasias: Conditions such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia, as methotrexate can further suppress bone marrow function.
- Active serious infections: Including tuberculosis, HIV, and other severe or opportunistic infections, as methotrexate suppresses immune function.
- Immunodeficiency syndromes: Pre-existing conditions that compromise immune function.
- Hypersensitivity: Known allergy to methotrexate or any of the excipients in the formulation.
- Concurrent live vaccination: Live vaccines must not be administered during methotrexate treatment due to the risk of disseminated infection.
Warnings and Precautions
For rheumatoid arthritis, psoriasis, and other autoimmune conditions, methotrexate must be taken once weekly only. Accidental daily administration of weekly-prescribed methotrexate doses has resulted in fatal toxicity. Patients must clearly understand their dosing schedule. Choose a specific day of the week and take all tablets on that single day.
Several important warnings and precautions apply to methotrexate therapy:
- Hepatotoxicity: Methotrexate can cause liver fibrosis and cirrhosis with prolonged use, often without symptoms. Liver function tests should be performed regularly. Risk is increased by alcohol consumption, obesity, diabetes, and pre-existing liver disease. Persistent elevations in ALT or AST may warrant dose reduction or discontinuation.
- Myelosuppression: Methotrexate can suppress bone marrow function, leading to leukopenia, anemia, or thrombocytopenia. Complete blood counts must be monitored regularly. Patients with renal impairment, folate deficiency, or advanced age are at higher risk.
- Pulmonary toxicity: Methotrexate pneumonitis is an uncommon but potentially serious adverse effect that can occur at any time during treatment and at any dose. Symptoms include dry cough, dyspnea, and fever. Chest X-ray may show diffuse interstitial infiltrates. Treatment must be discontinued immediately if methotrexate pneumonitis is suspected.
- Infections: Due to immunosuppression, patients on methotrexate are at increased risk of bacterial, viral, fungal, and opportunistic infections. Treatment should be interrupted during acute infections. Patients should be screened for hepatitis B, hepatitis C, and tuberculosis before starting therapy.
- Renal toxicity: Methotrexate can cause renal damage, particularly at high doses. Adequate hydration is important, and concomitant use of nephrotoxic drugs should be avoided where possible.
- Gastrointestinal toxicity: Stomatitis, nausea, and diarrhea are common. Ulcerative stomatitis may require dose reduction. Hemorrhagic enteritis and intestinal perforation have been reported rarely.
- Lymphoproliferative disorders: There have been reports of lymphoma and other lymphoproliferative disorders in patients receiving low-dose methotrexate, some of which regressed after discontinuation of the drug.
Pregnancy and Breastfeeding
Methotrexate is classified as a pregnancy Category X drug by the FDA, meaning it is absolutely contraindicated in pregnancy. It is one of the most well-established human teratogens, with exposure during the first trimester associated with a pattern of congenital malformations known as methotrexate embryopathy, which includes craniofacial abnormalities, limb defects, and central nervous system anomalies. Methotrexate also causes miscarriage and fetal death.
Women of childbearing potential must have a negative pregnancy test before starting methotrexate therapy, and reliable contraception must be used throughout treatment. After discontinuing methotrexate, women should wait at least 6 months before attempting conception to allow complete clearance of the drug and its metabolites. Similarly, men taking methotrexate should use effective contraception and wait at least 3 months after stopping treatment before fathering a child, as methotrexate can affect sperm quality and DNA integrity.
Methotrexate is excreted in human breast milk. Breastfeeding is contraindicated during methotrexate therapy and for at least one week after the last dose due to the potential for serious adverse effects in the nursing infant, including immunosuppression and effects on growth and development.
If you are planning to become pregnant, discuss alternative treatment options with your rheumatologist well in advance. Several medications for rheumatoid arthritis and psoriasis are considered compatible with pregnancy, including hydroxychloroquine and sulfasalazine. Your doctor will help you create a plan for safely transitioning medications before conception.
How Does Methotrexate Afortas Interact with Other Drugs?
Methotrexate undergoes renal tubular secretion as a major route of elimination, and its polyglutamate metabolites accumulate intracellularly over time. Because of these pharmacokinetic properties, several medications can significantly alter methotrexate blood levels or potentiate its toxic effects. Understanding these interactions is essential for safe prescribing and for patients to communicate effectively with all their healthcare providers about their complete medication list.
Major Interactions
| Interacting Drug/Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduced renal clearance of methotrexate; competition for tubular secretion | Increased methotrexate levels; increased risk of myelosuppression, nephrotoxicity | Use with caution at low MTX doses; avoid at high doses; monitor blood counts closely |
| Trimethoprim/Sulfamethoxazole | Additive antifolate effect; displacement from protein binding | Severe pancytopenia, potentially fatal bone marrow suppression | Avoid combination; use alternative antibiotics (e.g., amoxicillin) |
| Proton Pump Inhibitors (omeprazole, esomeprazole) | Decreased renal clearance via inhibition of breast cancer resistance protein (BCRP) | Elevated methotrexate levels; increased toxicity risk | Consider H2-blockers as alternative; monitor if PPI essential |
| Penicillins (amoxicillin, piperacillin) | Reduced renal tubular secretion of methotrexate | Increased methotrexate concentrations and toxicity | Monitor methotrexate levels and blood counts; consider dose adjustment |
| Leflunomide | Additive hepatotoxicity and myelosuppression | Increased risk of pancytopenia and liver damage | Combination sometimes used under close specialist monitoring; requires more frequent blood tests |
| Live Vaccines (MMR, varicella, BCG, yellow fever) | Immunosuppression impairs vaccine response | Risk of disseminated vaccine infection; reduced vaccine efficacy | Contraindicated; use inactivated vaccines; hold MTX 2 weeks before and 4 weeks after inactivated vaccines if feasible |
| Alcohol | Additive hepatotoxicity | Significantly increased risk of liver fibrosis and cirrhosis | Minimize or avoid alcohol; monitor liver function more frequently |
Minor Interactions
Several additional interactions are worth noting, though they are generally less clinically significant at the low doses used for autoimmune conditions:
- Folic acid: High-dose folic acid (more than 5 mg daily) may theoretically reduce methotrexate efficacy by competing at the cellular level. However, standard supplementation doses (5 mg weekly) do not appear to reduce therapeutic efficacy and are strongly recommended to mitigate side effects.
- Theophylline: Methotrexate may decrease theophylline clearance; monitor theophylline levels if used concurrently.
- Ciprofloxacin and other fluoroquinolones: May reduce renal tubular secretion of methotrexate; monitor for toxicity.
- Retinoids (acitretin, isotretinoin): Combination with methotrexate increases the risk of hepatotoxicity; generally avoid concurrent use.
- Cyclosporine: The combination may increase methotrexate levels and enhance immunosuppression; requires close monitoring.
Most guidelines recommend taking folic acid 5 mg once weekly (on a different day from methotrexate) or 1 mg daily (except on the methotrexate day) to reduce gastrointestinal and mucosal side effects. A Cochrane review has confirmed that folic acid supplementation reduces the incidence of hepatotoxicity, gastrointestinal symptoms, and stomatitis without compromising the efficacy of methotrexate in rheumatoid arthritis. Folinic acid (leucovorin) may be used as an alternative in patients who do not tolerate folic acid.
What Is the Correct Dosage of Methotrexate Afortas?
Correct dosing of methotrexate is critically important because the dosing schedule differs fundamentally between its autoimmune/inflammatory use and its oncological use. For all autoimmune and inflammatory conditions, methotrexate is administered as a single dose once per week on a specific designated day. The patient should choose a consistent day of the week (for example, every Monday) and take all the prescribed tablets on that day. This once-weekly schedule must be clearly understood by the patient, as accidental daily dosing has been a well-documented cause of serious and fatal adverse events.
Adults
Rheumatoid Arthritis
- Starting dose: 7.5 mg (3 tablets) once weekly, often starting at 10–15 mg weekly in current practice per ACR/EULAR guidelines
- Dose titration: Increase by 2.5–5 mg every 2–4 weeks based on clinical response and tolerability
- Target dose: 15–25 mg once weekly (most patients respond at 15–20 mg weekly)
- Maximum dose: 25–30 mg once weekly (oral bioavailability plateaus above 15 mg; consider subcutaneous route for doses above this)
- Onset of action: 4–8 weeks; full effect may take 3–6 months
Severe Psoriasis
- Starting dose: 7.5–10 mg (3–4 tablets) once weekly
- Dose titration: Increase gradually by 2.5 mg per week until adequate response
- Target dose: 10–25 mg once weekly
- Alternative schedule: Some protocols divide the weekly dose into three doses given at 12-hour intervals over a 24-hour period (e.g., 2.5 mg at 8 AM, 2.5 mg at 8 PM, and 2.5 mg at 8 AM the next day)
Psoriatic Arthritis
- Dosing: Same as for rheumatoid arthritis: 7.5–25 mg once weekly
- Titration: Adjust based on joint response and skin involvement
Children
Methotrexate may be used in children for juvenile idiopathic arthritis (JIA) under specialist supervision, typically at a dose of 10–15 mg/m² body surface area once weekly. The subcutaneous route is often preferred in pediatric patients due to more reliable bioavailability. Dosing in children should always be determined and monitored by a pediatric rheumatologist. The 2.5 mg tablet formulation may be used for children who can swallow tablets, but exact dosing must be calculated by the specialist.
Elderly
Elderly patients (over 65 years) may require dose reductions due to decreased renal function, reduced hepatic reserve, and lower folate stores. A lower starting dose of 5–7.5 mg weekly is often recommended with slower titration. Renal function should be carefully assessed before and during treatment, as age-related decline in glomerular filtration rate can lead to methotrexate accumulation. More frequent monitoring of blood counts and liver function is advisable in elderly patients.
Missed Dose
If you miss your scheduled weekly dose of methotrexate, take it as soon as you remember within 1–2 days of the missed dose. If more than 2 days have passed, skip the missed dose entirely and take your next dose on the regular scheduled day. Do not take a double dose to make up for a missed one. If you frequently forget your methotrexate day, consider using a pill organizer or setting a weekly alarm. Contact your doctor if you have missed several consecutive doses, as they may need to reassess your treatment plan.
Overdose
Methotrexate overdose is a medical emergency. The primary antidote is folinic acid (leucovorin calcium), which should be administered as soon as possible. If you suspect an overdose or have accidentally taken methotrexate daily instead of weekly, seek emergency medical attention immediately. Call your local emergency number or poison control center. Key signs of overdose include severe mouth sores, bloody vomit or stools, high fever, bruising or unusual bleeding, extreme fatigue, and decreased urine output.
In the event of methotrexate overdose, treatment consists of leucovorin rescue, aggressive intravenous hydration, urinary alkalinization to enhance renal excretion, and supportive care for bone marrow suppression. The prognosis depends on the degree of overdose, the time to treatment initiation, and the patient’s baseline organ function. Reports of fatal outcomes have been associated with accidental daily dosing of methotrexate tablets prescribed for weekly use, underscoring the critical importance of clear patient education about dosing schedules.
| Indication | Starting Dose | Target Dose | Frequency | Notes |
|---|---|---|---|---|
| Rheumatoid Arthritis | 7.5–15 mg | 15–25 mg | Once weekly | Titrate every 2–4 weeks; add folic acid |
| Severe Psoriasis | 7.5–10 mg | 10–25 mg | Once weekly | Response in 4–8 weeks; consider subcutaneous if poor oral absorption |
| Psoriatic Arthritis | 7.5–15 mg | 15–25 mg | Once weekly | Addresses both skin and joint manifestations |
| Juvenile Idiopathic Arthritis | 10–15 mg/m² | 10–15 mg/m² | Once weekly | Specialist supervision required; subcutaneous preferred |
| Elderly (>65 years) | 5–7.5 mg | 10–20 mg | Once weekly | Assess renal function; slower titration; closer monitoring |
What Are the Side Effects of Methotrexate Afortas?
Like all medications, methotrexate can cause side effects, although not everyone experiences them. The side effect profile of low-dose methotrexate (used for autoimmune conditions) differs from high-dose methotrexate used in oncology. Many common side effects can be mitigated by concurrent folic acid supplementation, adequate hydration, and taking methotrexate in the evening or with food. It is important to understand which side effects require medical attention and which may be managed with supportive measures.
The following side effects are classified according to the standard frequency categories based on clinical trial data and post-marketing surveillance:
Very Common (affects more than 1 in 10 people)
Frequency: >10%
- Nausea and loss of appetite
- Elevated liver enzymes (ALT, AST)
- Fatigue and malaise
- Stomatitis (mouth sores and oral ulceration)
- Abdominal discomfort
Common (affects 1 in 10 to 1 in 100 people)
Frequency: 1–10%
- Headache and dizziness
- Diarrhea
- Leukopenia (low white blood cell count)
- Thrombocytopenia (low platelet count)
- Alopecia (hair thinning or loss, usually reversible)
- Skin rash and photosensitivity
- Decreased resistance to infections
- Vomiting
Uncommon (affects 1 in 100 to 1 in 1,000 people)
Frequency: 0.1–1%
- Pneumonitis (methotrexate lung toxicity) — dry cough, fever, breathlessness
- Liver fibrosis
- Pancytopenia (suppression of all blood cell lines)
- Renal impairment
- Interstitial nephritis
- Vasculitis
- Herpes zoster reactivation
- Mood changes and cognitive impairment (“methotrexate fog”)
Rare (affects fewer than 1 in 1,000 people)
Frequency: <0.1%
- Severe hepatotoxicity (cirrhosis)
- Agranulocytosis (severe neutropenia)
- Aplastic anemia
- Lymphoproliferative disorders (including lymphoma)
- Stevens-Johnson syndrome / toxic epidermal necrolysis
- Opportunistic infections (Pneumocystis jirovecii pneumonia, disseminated herpes)
- Anaphylaxis
- Seizures and leukoencephalopathy
- Osteoporosis (with prolonged use)
Contact your doctor or seek emergency care immediately if you experience: unexplained bruising or bleeding, persistent sore throat or fever (signs of infection), severe shortness of breath or dry cough, yellowing of the skin or eyes (jaundice), black tarry stools or blood in vomit, severe mouth ulcers preventing eating or drinking, or persistent severe abdominal pain. These may indicate serious adverse effects requiring urgent medical evaluation.
Many of the gastrointestinal side effects of methotrexate (nausea, stomatitis, fatigue) can be significantly reduced by folic acid supplementation. A systematic review published in the Cochrane Database confirmed that folic acid or folinic acid supplementation reduces the incidence of gastrointestinal side effects, liver enzyme elevations, and the rate of methotrexate withdrawal due to adverse events. Other strategies to manage nausea include taking methotrexate in the evening, taking it with food, or splitting the dose across the day on the designated dosing day. If oral methotrexate is poorly tolerated, switching to subcutaneous administration often significantly improves gastrointestinal tolerability.
How Should You Store Methotrexate Afortas?
Proper storage of methotrexate is important both to maintain the medication’s stability and to prevent accidental exposure by others, particularly children and pregnant women. Methotrexate is a cytotoxic and teratogenic substance, and contact should be minimized.
Store the tablets at room temperature below 25°C (77°F). Keep the tablets in their original packaging (blister pack or container) to protect from light and moisture. Do not transfer tablets to a different container unless it provides equivalent protection. Store methotrexate separately from other medications to avoid confusion, and clearly label the container with the weekly dosing day if possible.
Keep Methotrexate Afortas securely out of sight and reach of children. Due to its teratogenic properties, the medication should be stored away from areas accessible to pregnant women or women who may become pregnant. If a tablet is broken or crushed, avoid inhaling the powder or getting it on the skin; if skin contact occurs, wash the area immediately with soap and water.
Do not use Methotrexate Afortas after the expiry date printed on the packaging. Do not dispose of unused or expired tablets in household waste or via the sink or toilet. Return unused medication to a pharmacy or follow local regulations for the disposal of cytotoxic waste.
What Does Methotrexate Afortas Contain?
The active ingredient in Methotrexate Afortas is methotrexate, present at a strength of 2.5 mg per tablet. Methotrexate is chemically known as N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid. It is a structural analogue of folic acid and acts as a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR).
The inactive ingredients (excipients) in the tablet formulation typically include:
- Lactose monohydrate — a filler/diluent (patients with lactose intolerance should be aware)
- Microcrystalline cellulose — a binder and filler
- Maize starch — a disintegrant
- Magnesium stearate — a lubricant
- Sodium starch glycolate — a disintegrant to aid tablet dissolution
The 2.5 mg tablet strength is the standard formulation used worldwide for methotrexate in autoimmune and inflammatory conditions. The low individual tablet strength allows precise dose adjustments in 2.5 mg increments, which is particularly important during dose titration and for elderly patients or those with renal impairment who may require lower doses. Some tablets are scored (marked with a break line) to facilitate splitting into halves for 1.25 mg dose increments if needed, though this should only be done on medical advice.
If you have any known allergies to the excipients listed above, or if you have severe lactose intolerance, inform your doctor before starting Methotrexate Afortas. Alternative formulations or routes of administration (such as subcutaneous injection solutions) may be available.
What Monitoring Is Required During Methotrexate Treatment?
Monitoring is one of the most critical aspects of safe methotrexate therapy. Because methotrexate can affect the bone marrow, liver, kidneys, and lungs, a structured monitoring program is essential to detect potential adverse effects early, before they become clinically significant. Both the ACR and BSR (British Society for Rheumatology) have published detailed monitoring guidelines that your healthcare provider will follow.
Baseline Investigations (Before Starting Treatment)
- Complete blood count (CBC) with differential
- Liver function tests (ALT, AST, albumin, bilirubin)
- Renal function tests (serum creatinine, estimated GFR)
- Hepatitis B and C serology
- Chest X-ray (baseline for comparison if pulmonary symptoms develop)
- Pregnancy test for women of childbearing potential
- Screening for tuberculosis in patients with risk factors
- Varicella immunity assessment in patients without clear history of chickenpox
Ongoing Monitoring Schedule
| Phase | Timeframe | Frequency | Tests Required |
|---|---|---|---|
| Initiation | First month | Every 1–2 weeks | CBC, LFTs, creatinine |
| Dose titration | Months 2–6 | Monthly | CBC, LFTs, creatinine |
| Stable dose | After 6 months | Every 2–3 months | CBC, LFTs, creatinine, albumin |
| Dose increase | After any dose change | 2–4 weeks after change | CBC, LFTs, creatinine |
If any abnormalities are detected in blood tests, your doctor will determine the appropriate action. This may include temporary dose reduction, treatment interruption until values normalize, additional investigations (such as liver biopsy for persistent liver enzyme elevations), or permanent discontinuation if serious toxicity is identified. You should never alter your methotrexate dose or stop taking it without consulting your doctor, as abrupt changes can lead to disease flare.
Frequently Asked Questions About Methotrexate Afortas
Methotrexate Afortas is a prescription medication used to treat rheumatoid arthritis, psoriasis, psoriatic arthritis, and certain types of cancer. In rheumatoid arthritis, it is the first-line disease-modifying antirheumatic drug (DMARD) recommended by international guidelines. It works by suppressing the overactive immune system and reducing inflammation. For autoimmune conditions, it is taken once weekly, not daily.
For autoimmune conditions like rheumatoid arthritis and psoriasis, methotrexate is taken once weekly because this dosing schedule provides effective immunosuppression while minimizing toxicity. Taking methotrexate daily for these conditions is a serious and potentially fatal dosing error. The once-weekly regimen allows the body to recover between doses and reduces the risk of bone marrow suppression, liver damage, and other serious side effects. Always follow your doctor’s prescribed schedule exactly.
Regular blood monitoring is essential while taking methotrexate. You will typically need a complete blood count (CBC), liver function tests (ALT, AST, albumin), and renal function tests (creatinine, eGFR). Blood tests are usually performed every 1–2 weeks during the first month, then monthly for the first 6 months, and every 2–3 months thereafter once stable. Your doctor may adjust the monitoring frequency based on your individual risk factors.
No. Methotrexate is absolutely contraindicated during pregnancy as it is a known teratogen that causes severe birth defects and miscarriage. Both women and men must use reliable contraception during treatment and for at least 6 months (women) or 3 months (men) after stopping methotrexate. If you are planning pregnancy, discuss alternative treatments with your doctor well in advance. A pregnancy test is required before starting methotrexate therapy in women of childbearing potential.
Alcohol consumption should be minimized or avoided while taking methotrexate, as both methotrexate and alcohol are metabolized by the liver and the combination significantly increases the risk of hepatotoxicity (liver damage). Current guidelines from the ACR and EULAR recommend limiting alcohol intake. If you do drink, it should be infrequent and in small amounts, and your liver function should be monitored more closely. Discuss your alcohol consumption honestly with your doctor.
If you have accidentally taken methotrexate daily instead of weekly, stop taking it immediately and seek urgent medical attention. Daily dosing of methotrexate prescribed for weekly use is a medical emergency that can cause severe bone marrow suppression (pancytopenia), life-threatening infections, kidney failure, and liver failure. Treatment with folinic acid (leucovorin rescue) may be needed. Contact your doctor, go to the emergency department, or call your local poison control center immediately.
References
This article is based on peer-reviewed medical literature, international clinical guidelines, and official drug labeling. All medical claims are supported by Level 1A evidence where available.
- Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924–939. doi:10.1002/acr.24596
- Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):3–18. doi:10.1136/ard-2022-223356
- Shea B, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2013;(5):CD000951. doi:10.1002/14651858.CD000951.pub2
- Lopez-Olivo MA, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2014;(6):CD000957. doi:10.1002/14651858.CD000957.pub2
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- European Medicines Agency. Methotrexate – Article 31 referral: Measures to prevent dosing errors. EMA/79884/2019. London: EMA; 2019.
- Mease PJ, et al. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–441. doi:10.1007/s40265-014-0191-y
- Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the Rheumatic Diseases. 2009;68(7):1094–1099. doi:10.1136/ard.2008.092668
- Kremer JM. Toward a better understanding of methotrexate. Arthritis & Rheumatism. 2004;50(5):1370–1382. doi:10.1002/art.20278
- BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2017;56(6):865–868. doi:10.1093/rheumatology/kew479
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians with expertise in rheumatology, dermatology, clinical pharmacology, and internal medicine.
iMedic Medical Editorial Team — Specialists in Rheumatology and Clinical Pharmacology with documented academic background and clinical experience in the management of autoimmune diseases.
iMedic Medical Review Board — Independent panel of medical experts who review all content according to international guidelines (ACR, EULAR, WHO, EMA, FDA). All content follows the GRADE evidence framework.
All medical content on iMedic is evidence-based and follows international clinical guidelines. We have no commercial funding, no pharmaceutical company sponsorship, and no advertising. Our goal is to provide accurate, accessible, and trustworthy medical information for everyone. Read our full editorial standards.